Acinetobacter baumannii: Emergence of a Successful Pathogen
Acinetobacter baumannii has emerged as a highly troublesome pathogen for many
institutions globally. As a consequence of its immense ability to acquire or upregulate …
institutions globally. As a consequence of its immense ability to acquire or upregulate …
Polymyxins revisited
D Landman, C Georgescu, DA Martin… - Clinical microbiology …, 2008 - Am Soc Microbiol
The global emergence of multidrug-resistant gram-negative bacilli has spurred a renewed
interest in polymyxins. Once discarded due to concerns regarding nephrotoxicity and …
interest in polymyxins. Once discarded due to concerns regarding nephrotoxicity and …
Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing
LM Lim, N Ly, D Anderson, JC Yang… - … : The Journal of …, 2010 - Wiley Online Library
Colistin is a polymyxin antibiotic that was discovered in the late 1940s for the treatment of
gram‐negative infections. After several years of clinical use, its popularity diminished …
gram‐negative infections. After several years of clinical use, its popularity diminished …
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections
Institutional outbreaks caused by Acinetobacter baumannii strains that have acquired
multiple mechanisms of antimicrobial drug resistance constitute a growing public-health …
multiple mechanisms of antimicrobial drug resistance constitute a growing public-health …
[HTML][HTML] Colistin: new lessons on an old antibiotic
D Yahav, L Farbman, L Leibovici, M Paul - Clinical microbiology and …, 2012 - Elsevier
Colistin has been re-introduced into clinical practice for the treatment of carbapenem-
resistant Gram-negative bacteria. Studies in the last decade attempted to reconstruct the …
resistant Gram-negative bacteria. Studies in the last decade attempted to reconstruct the …
Multidrug-resistant Gram-negative infections: what are the treatment options?
The emergence of multidrug-resistant (MDR) Gram-negative bacilli creates a challenge in
the treatment of nosocomial infections. While the pharmaceutical pipeline is waning, two …
the treatment of nosocomial infections. While the pharmaceutical pipeline is waning, two …
Multidrug-resistant Gram-negative bacteria: how to treat and for how long
H Giamarellou - International journal of antimicrobial agents, 2010 - Elsevier
The emergence of multidrug-resistant (MDR) Gram-negative bacilli creates a big problem for
the treatment of nosocomial infections. As the pharmaceutical pipeline wanes, the only …
the treatment of nosocomial infections. As the pharmaceutical pipeline wanes, the only …
Global Spread of Drug-Resistant Acinetobacter Baumannii: Molecular Epidemiology And Management Of Antimicrobial Resistance
Acinetobacter baumannii is an opportunistic Gram-negative pathogen with increasing
relevance in a variety of hospital-acquired infections especially among intensive care unit …
relevance in a variety of hospital-acquired infections especially among intensive care unit …
Potent Synergy and Sustained Bactericidal Activity of a Vancomycin-Colistin Combination versus Multidrug-Resistant Strains of Acinetobacter baumannii
NC Gordon, K Png, DW Wareham - Antimicrobial agents and …, 2010 - Am Soc Microbiol
Multidrug-resistant Acinetobacter baumannii (MDRAB) presents an increasing challenge to
health care. Although colistin has been used as a treatment of last resort, there is concern …
health care. Although colistin has been used as a treatment of last resort, there is concern …
[HTML][HTML] Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies
N Petrosillo, E Ioannidou, ME Falagas - Clinical Microbiology and Infection, 2008 - Elsevier
Colistin is commonly the last resort for treatment of infections caused by multidrug-resistant
Gram-negative bacteria. In clinical practice, it is frequently used as combination therapy in …
Gram-negative bacteria. In clinical practice, it is frequently used as combination therapy in …